Market capitalization | $3.60m |
Enterprise Value | $31.29m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 23.89 |
P/S ratio (TTM) P/S ratio | 2.75 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 6.36% |
Revenue (TTM) Revenue | $1.31m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | 1.31 1.31 |
7%
7%
|
|
Gross Profit | 0.24 0.24 |
20%
20%
|
|
EBITDA | -3.50 -3.50 |
57%
57%
|
EBIT (Operating Income) EBIT | -3.80 -3.80 |
56%
56%
|
Net Profit | -15 -15 |
60%
60%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and provision of healthcare services. It operates through the following segments: Real Property Operating; Medical Related Consulting Services; and Development Services and Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.
Head office | United States |
CEO | David Jin |
Employees | 5 |
Founded | 2014 |
Website | www.avalon-globocare.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.